Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II Clinical Trial.
This study is currently recruiting participants.
Verified March 2013 by Grupo Español de Investigación en Neurooncología
Sponsor:
Grupo Español de Investigación en Neurooncología
Collaborator:
Pfizer
Information provided by (Responsible Party):
Grupo Español de Investigación en Neurooncología
ClinicalTrials.gov Identifier:
NCT01520870
First received: January 18, 2012
Last updated: March 8, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | July 2015 |
| Estimated Primary Completion Date: | January 2014 (Final data collection date for primary outcome measure) |